UBS Finds Over A Million Americans Using “Unapproved” Compounded GLP-1s Shares of Danish pharmaceutical giant Novo Nordisk have experienced a sharp sell-off this week after slashing its full-year sales and profit guidance, citing softening Wegovy demand driven by compounded GLP-1 headwinds. If losses hold through Friday, the magnitude of the drawdown will mark the largest weekly decline ever for the stock trading in Copenhagen. A key question right now among some institutional investors: Has the correction created a compelling entry point in Novo? Let’s start with the technicals: Shares on the week are down about 29%, the largest weekly decline ever… — Continue at ZeroHedge News : Read More
